Study period | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Enrolment | Allocation | Post-allocation | Close-out | ||||||||
Timepoint (time in weeks) | −t1 | 0 | 1 | 3 | 5 | 7 | 9 | 11 | 14 (+/−1)* | 16 | 26 |
Enrolment | |||||||||||
Consent and screening | X | ||||||||||
Randomisation | X | ||||||||||
Allocation | X | ||||||||||
Intervention | |||||||||||
Telephone call 1 | X | ||||||||||
Telephone call 2 | X | ||||||||||
Telephone call 3 | X | ||||||||||
Telephone call 4 | X | ||||||||||
Telephone call 5 | X | ||||||||||
Telephone call 6 | X | ||||||||||
Booster telephone call | X | ||||||||||
Assessments | |||||||||||
Baseline assessments | |||||||||||
Two fatigue screening questions PHQ-9 GAD-7 SF-SIS cognitive item SF-SIS language item Screening questions about serious illness | X | ||||||||||
4 months follow-up assessments | |||||||||||
FAS PHQ-9 GAD-7 CBRQ EQ-5D-5 L | X | ||||||||||
6 months follow-up assessments | |||||||||||
FAS PHQ-9 GAD-7 CBRQ SF-SIS EQ-5D-5 L Anxiolytics (Y/N) Hours working Health costs | X |